BridgeBio

Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, specializing in the development of therapies for diseases associated with transthyretin (TTR) amyloidosis (ATTR). Founded in 2013, the company is advancing its lead candidate, AG10, which is currently undergoing phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize tetrameric TTR, aiming to interrupt the pathological processes that lead to ATTR. As a subsidiary of BridgeBio Pharma, Eidos Therapeutics is committed to addressing the clinical needs related to TTR and amyloidosis through innovative, genetically targeted therapies.

Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, specializing in the development of therapies for diseases associated with transthyretin (TTR) amyloidosis (ATTR). Founded in 2013, the company is advancing its lead candidate, AG10, which is currently undergoing phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize tetrameric TTR, aiming to interrupt the pathological processes that lead to ATTR. As a subsidiary of BridgeBio Pharma, Eidos Therapeutics is committed to addressing the clinical needs related to TTR and amyloidosis through innovative, genetically targeted therapies.

QED Therapeutics, Inc. is a biotechnology company based in San Francisco, California, founded in 2017 as a subsidiary of BridgeBio Pharma. The company specializes in developing precision medicines targeting diseases associated with Fibroblast growth factors and their receptors (FGFR). QED's lead candidate, infigratinib, is a best-in-class FGFR kinase inhibitor that has demonstrated significant clinical efficacy in patients with chemotherapy-refractory cholangiocarcinoma harboring FGFR2 fusions. In addition to cholangiocarcinoma, QED is exploring the potential of infigratinib in preclinical studies for treating achondroplasia and aims to expand its development into other FGFR-driven tumor types and rare disorders.

PellePharm, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for skin cancer, particularly targeting basal cell carcinoma (BCC) and basal cell nevus syndrome. Founded in 2012 and headquartered in Menlo Park, California, the company is advancing patidegib, a first-in-class topical hedgehog pathway inhibitor. This novel formulation aims to reduce the tumor burden in patients by decreasing the number of surgically-eligible basal cell carcinomas, thereby potentially minimizing the need for invasive surgeries and the associated scarring. Currently, patidegib is undergoing phase 2 clinical trials for the treatment of sporadic BCCs, with the goal of improving patient quality of life through a less painful and more manageable treatment approach.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.